Advanced glycation end-products in diabetic nephropathy.
Throughout the industrialized (well-fed) world, diabetes mellitus is the most prevalent cause of end-stage renal disease (ESRD). Diabetic nephropathy is as likely to develop in long-duration non-insulin-dependent diabetes (type 2) as in insulin-dependent diabetes mellitus (type 1). Nephropathy in diabetes follows a well outlined course, starting with microalbuminuria through proteinuria, azotaemia and culminating in ESRD. Renal functional decline in diabetic nephropathy is slowed by establishment of euglycaemia and normalization of hypertensive blood pressure. Diabetic ESRD patients, compared with other causes of ESRD, sustain greater mortality and morbidity due to concomitant systemic disorders, especially coronary artery and cerebrovascular disease. A central role for glucose toxicity, especially the adverse impact of accumulated advanced glycosylated end-products (AGEs), appears likely from experimental data generated both in induced diabetic rodents and diabetic individuals. Treatment with aminoguanidine raises the possibility of blocking end-organ damage in diabetes without the necessity for correcting hyperglycaemia.
Friedman
E A
EA
Department of Medicine, State University of New York, Brooklyn 11203, USA.
D000818:Animals; D003928:Diabetic Nephropathies / Q000209:etiology* / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005947:Glucose / Q000633:toxicity; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control / Q000628:therapy; D016030:Kidney Transplantation; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000378:metabolism; D006435:Renal Dialysis; D012307:Risk Factors
D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; D005947:Glucose; C004479:pimagedine